"Dr. Lee Shettle sees all of his patients himself to establish a more personal relationship. He is dedicated and committed to taking the time to help each and every patient understand their unique visual, medical or surgical condition, personally giving them the best possible options in the decision-making process for their illness. He believes a patient who understands the reasons or mechanisms as to why they have a certain condition greatly improves their prognosis and can provide them with the best visual outcome."

During the past decade, Shettle Eye Research Inc conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 13 clinical trials were completed, i.e. on average, 65% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 13 clinical trials were completed. i.e. 185.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shettle Eye Research Inc" #1 sponsor was "Santen Inc." with 4 trials, followed by "Kala Pharmaceuticals, Inc." with 3 trials sponsored, "Aerie Pharmaceuticals" with 2 trials sponsored, "RVL Pharmaceuticals, Inc." with 2 trials sponsored and "Shire" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shettle Eye Research Inc" #1 collaborator was "IQVIA Biotech" with 1 trials as a collaborator and "National Eye Institute (NEI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Shettle Eye Research Inc" are "Dry Eye" (3 trials), "Ocular Hypertension" (3 trials), "Blepharoptosis" (2 trials), "Dry Eye Syndromes" (2 trials) and "Glaucoma" (2 trials). Many other conditions were trialed in "Shettle Eye Research Inc" in a lesser frequency.

Most popular intervention types in "Shettle Eye Research Inc" are "Drug" (19 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "DE-117 Ophthalmic Solution" (2 trials), "KPI-121 0.25% Ophthalmic Suspension" (2 trials), "RVL-1201" (2 trials) and "SHP640" (2 trials). Other intervention names were less common.

The vast majority of trials in "Shettle Eye Research Inc" are 20 trials for "All" genders.

Currently, there are NaN active trials in "Shettle Eye Research Inc". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Shettle Eye Research Inc, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Shettle Eye Research Inc, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".